文献速递头颈部肿瘤放疗放疗物理与技术

头颈部SBRT再程放疗后颈动脉剂量与颈动脉破裂综合征风险

Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-05

回顾性分析75例既往已放疗的头颈部复发癌患者(150条颈动脉),接受中位44 Gy/5次、每周两次的SBRT,中位随访8个月。共4例出血事件(5.3%),其中2例死于颈动脉破裂综合征;

要点

  • 5次非连续日SBRT再程放疗后出血风险低,即使肿瘤完全包绕颈动脉。
  • D1cc、D2cc及平均颈动脉剂量与出血事件无显著关联。
  • D0.1cc<47.6 Gy时未观察到颈动脉破裂综合征。

核心结论

  • 5次非连续日SBRT再程放疗后出血风险低,即使肿瘤完全包绕颈动脉。
  • 剂量体积参数与颈动脉出血风险无显著关联,但事件数少限制了统计效能。
  • D0.1cc<47.6 Gy时未观察到颈动脉破裂综合征。

研究设计与样本

  • 单中心回顾性研究,纳入2008年1月至2013年3月收治的75例既往已放疗的头颈部复发癌患者,共分析150条颈动脉。
  • 全部患者接受基于直线加速器的SBRT,中位剂量44 Gy(范围40–50 Gy),分5次、每周两次照射。
  • 63例(84%)同期接受西妥昔单抗治疗。
  • 颈动脉双侧common、internal、external段在PTV上下各2 cm范围勾画,记录D0.1cc、D1cc、D2cc及平均剂量。
  • 采用二元逻辑回归分析剂量参数与颈动脉出血事件的关联。

主要发现

  • 全组中位随访8个月(范围1–91个月),存活患者中位随访37个月(范围31–91个月)。
  • 中位再程放疗间隔20个月(范围3–423个月),中位既往放疗剂量70 Gy(范围52.5–140 Gy)。
  • 全组颈动脉D0.1cc、D1cc、D2cc及平均剂量中位值分别为40.8 Gy(IQR 21.6–47.6 Gy)、26.8 Gy(IQR 14.1–42.1 Gy)、15.4 Gy(IQR 8.4–32.7 Gy)和15.0 Gy(IQR 8.9–23.3 Gy)。
  • 共4例出血事件(5.3%):2例(2.7%)黏膜出血经颈动脉分支栓塞后缓解,2例(2.7%)死于颈动脉破裂综合征并发症;2例CBOS患者D0.1cc分别为48.4 Gy和47.6 Gy。

关键数值与推荐

  • SBRT方案:中位44 Gy(范围40–50 Gy)分5次,每周两次非连续日照射。
  • 颈动脉剂量体积参数记录:D0.1cc、D1cc、D2cc及平均剂量。
  • 全组中位D0.1cc为40.8 Gy(IQR 21.6–47.6 Gy),中位D1cc为26.8 Gy(IQR 14.1–42.1 Gy),中位D2cc为15.4 Gy(IQR 8.4–32.7 Gy),中位平均剂量为15.0 Gy(IQR 8.9–23.3 Gy)。
  • D0.1cc<47.6 Gy时未观察到颈动脉破裂综合征。

临床怎么用

  • 头颈部再程SBRT采用5次非连续日照射时,即使肿瘤完全包绕颈动脉,出血风险也较低。
  • D0.1cc<47.6 Gy时未观察到CBOS,可作为临床参考的剂量观察值。
  • D1cc、D2cc及平均颈动脉剂量与出血风险无显著关联,但需结合事件数少的特点谨慎解读。

局限性

  • 回顾性研究,早期111例因剂量学不完整被排除,可能存在选择偏倚。
  • 出血事件仅4例(含2例CBOS),事件数少限制统计效能。
  • 中位随访8个月,存活患者37个月,晚期事件可能未完全捕获。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To correlate carotid dose and risk of carotid blowout syndrome (CBOS) after stereotactic body radiation therapy (SBRT), hypothesizing that carotid dose does not correlate with CBOS. METHODS AND MATERIALS: We retrospectively reviewed 186 patients with recurrent, previously irradiated head and neck cancer treated between January 2008 and March 2013. Patients treated early in our experience with incomplete dosimetry were excluded from analysis (n = 111). A total of 75 patients were identified, providing 150 carotid arteries for analysis. Median follow-up was 8 months (range, 1-91 months) for all patients, and 37 months for surviving patients (range, 31-91 months). Patients were treated with linear accelerator-based SBRT to a median dose up to 44 Gy (range, 40-50 Gy) in 5 fractions delivered on a twice-weekly basis. Concurrent cetuximab was used in 63 patients (84%). The bilateral common, internal, and external carotid arteries were delineated 2 cm above and below the planning target volume. The maximum dose to 0.1 cm3 (D0.1cc), 1 cm3 (D1cc), and 2 cm3 (D2cc) of the carotid and the mean carotid dose from SBRT were recorded and analyzed for association with carotid bleeding events, using binary logistic regression. RESULTS: Median reirradiation interval was 20 months (range, 3-423 months), and median prior radiation dose was 70 Gy (range, 52.5-140 Gy). Sixteen patients (21.3%) received more than 1 course of SBRT, and the cumulative carotid doses from fused summary plans were recorded. The overall median D0.1cc, D1cc, D2cc, and mean carotid doses were 40.8 Gy (interquartile range [IQR], 21.6-47.6 Gy), 26.8 Gy (IQR, 14.1-42.1 Gy), 15.4 Gy (IQR, 8.4-32.7 Gy), and 15.0 Gy (IQR, 8.9-23.3 Gy), respectively. There were a total of 4 bleeding events (5.3%): 2 patients (2.7%) had mucosal bleeds that resolved after embolization of carotid branches, and 2 patients (2.7%) died from complications of CBOS. In the 2 patients with CBOS the D0.1cc was 48.4 Gy and 47.6 Gy, respectively. There was no significant association between bleeding events and D1cc (P = .280), D2cc (P = .571), or mean dose (P = .568). There was a trend toward increased risk of bleeding and D0.1cc (P = .080). CONCLUSIONS: These results demonstrate a low risk of bleeding after reirradiation with SBRT when 5 fractions are delivered on nonconsecutive days, even when tumor is completely encasing the carotid artery. Although limited by the low number of events, no significant association was found between dose-volume parameters and the risk of carotid bleeding. No CBOS was noted when D0.1cc was <47.6 Gy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gebhardt BJ, Vargo JA, Ling D, et al. Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29398127. doi:10.1016/j.ijrobp.2017.11.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。